Hemispherx Biopharma and United States Army Medical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has been informed by USAMRIID scientists that they have in-vitro data indicating that Alferon ® , the only multi-species, natural alpha interferon (IFN) commercially approved in the U.S., successfully protected human cells against the Ebola virus. Low concentrations of Ampligen ® , an experimental double-stranded (ds) RNA therapeutic, also successfully protected human cells against the Ebola virus USAMRIID plans to continue to collect data and to initiate in-vitro synergy studies using Alferon ® and Ampligen ® . Previous published studies have demonstrated synergy between Ampligen and alpha interferon with HIV. The overall effect is to establish a framework for clinical interventions in both preventative and therapeutic settings of Ebola virus disease (EVD) by rational combinations of the two experimental products to treat Ebola.

About Alferon® N

Alferon ® N is the only natural source, multi-species alpha interferon currently approved for sale in the U.S. Alferon ® N is approved in the U.S. only for the treatment of refractory or recurring external genital warts caused by human papilloma virus in patients 18 years of age or older.

Clinical trial data will be necessary to establish the human efficacy of Alferon ® N for EVD.

About Ampligen®

Ampligen ® , an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.  

Ebola virus specifically inhibits the dsRNA within cells via a sequestration process. Such RNA would otherwise cause a robust antiviral response to be mounted. Ampligen ® may be able to overcome this deficiency in host response. Clinical trial data will be necessary to establish the human efficacy of Ampligen ® for Ebola virus.

About USAMRIID

Since 1969, USAMRIID has served as the Department of Defense's (DoD) lead laboratory for medical biological defense research. While its core mission is to protect the warfighter from biological threats, it also investigates disease outbreaks and threats to public health. Research conducted at USAMRIID leads to medical solutions—therapeutics, vaccines, diagnostics, and information—that benefit both military personnel and civilians. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.  Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome.  Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.  For more information please visit www.hemispherx.net

Disclosure Notice

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties.  For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission.  The final results of these efforts and/or any other activities could vary materially from Hemispherx's expectations.  In vitro experiments are not necessarily predictive of clinical outcome and no representations are made that any products described in this release will be ultimately determined safe and effective in the prevention and/or treatment of the Ebola virus.  Moreover, it would take time, testing and funds to obtain approval of any such product and there are no assurances that a commercial approval for treatment of the Ebola virus can be obtained.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "potential," "potentially," "possible," and similar expressions are intended to identify forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved.  These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements.  Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.

Company/Investor Contact: Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 60

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 20

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 128

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 146

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 196

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 144

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 54

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading

Top 5 Most Recently Viewed Articles

Qubic's Game-Changing Milestone in Proof of Work Innovation

Updated Category News Views 335

Revolutionizing Mining: Qubic's Major Milestone Qubic, a decentralized compute and AI Layer 1 protocol, has reached a significant milestone with the successful implementation of its Useful Proof of Work (uPoW) concept. By harnessing the potential of merge mining with Monero and Tari, Qubic is setting a new standard in the mining industry and redefining the dynamics of...

Continue Reading
Global Ship Lease's Strong Q3 2024 Performance and Future Outlook

Updated Category News Views 187

Global Ship Lease Reports Impressive Third Quarter of 2024 Global Ship Lease, Inc. (NYSE: GSL), a key player in the containership ownership market, has recently revealed its unaudited financial results for the third quarter of 2024, reflecting strong operational performance and strategic positioning in an evolving maritime landscape. Quarterly Highlights: A Solid...

Continue Reading
Silverfort's New Security Features Enhance Identity Protection

Updated Category News Views 210

Enhancing Identity Security with Silverfort's New Capabilities Silverfort has recently announced exciting advancements in its identity security solutions, solidifying its leadership within the emerging identity verification and identity protection (IVIP) market. The introduction of Access Intelligence and Identity Graph & Inventory empowers organizations to proactively...

Continue Reading
Gabelli Multimedia Trust Maintains Steady Monthly Dividends

Updated Category News Views 306

Gabelli Multimedia Trust's Commitment to Shareholders The Gabelli Multimedia Trust Inc. (NYSE: GGT), located in RYE, N.Y., has reaffirmed its commitment to provide regular monthly cash distributions for its shareholders. This initiative emphasizes the Fund's dedication to maintaining a stable income stream, reflecting its solid financial strategies aimed at long-term...

Continue Reading
Shabodi Launches NetAware 2.1 to Transform Network Applications

Updated Category News Views 170

Shabodi Unveils NetAware 2.1: A Game-Changer for Programmable Networks Shabodi has proudly announced the launch of its innovative platform, NetAware 2.1, marking another significant stride in the realm of programmable networks. This advanced version embodies Shabodi's commitment to enhancing network-aware applications, offering a suite of capabilities that empower...

Continue Reading